Alternatives to Praluent If You Can't Fill Your Prescription

Praluent (alirocumab) is one of the most powerful cholesterol-lowering medications available, reducing LDL-C by up to 63% on top of statin therapy. But if you're stuck in prior authorization limbo, can't find it at a specialty pharmacy, or are facing prohibitive out-of-pocket costs, your cardiovascular risk doesn't pause. Here are the most effective alternatives to consider with your doctor.

Before Switching: Try to Resolve the Access Issue

Before changing your medication, it's worth trying to resolve the Praluent access issue first. medfinder calls pharmacies near you to check which ones have Praluent in stock and can fill your prescription — this alone resolves access problems for many patients who just need to find the right pharmacy.

Also confirm your prior authorization status and explore the MyPRALUENT Copay Card (commercially insured patients pay as little as $35–$50/month). If these steps don't resolve things, the alternatives below are worth discussing with your cardiologist or prescribing provider.

Alternative 1: Repatha (Evolocumab) — The Closest Match

Repatha (evolocumab) is the most direct alternative to Praluent. Both are PCSK9 inhibitor monoclonal antibodies with nearly identical mechanisms of action and similar LDL-C reduction (50–65%). Repatha is also a self-injected subcutaneous medication given every 2 weeks or once monthly.

Key reasons to consider Repatha:

Your insurance plan prefers Repatha on its formulary over Praluent

Your specialty pharmacy has Repatha in stock but not Praluent

The ODYSSEY OUTCOMES trial for Praluent and the FOURIER trial for Repatha showed comparable 15% relative reductions in major cardiovascular events

The Amgen Repatha Ready copay card can reduce costs to as low as $5/month for commercially insured patients — potentially even lower than Praluent's copay card savings.

Alternative 2: Leqvio (Inclisiran) — Twice-Yearly, In-Office Injections

Leqvio (inclisiran) is a newer type of LDL-lowering therapy that targets the PCSK9 pathway through a completely different mechanism — small interfering RNA (siRNA). Instead of blocking the PCSK9 protein, inclisiran prevents the liver from making PCSK9 in the first place, achieving similar LDL-C reductions (~50%) that last up to 6 months per injection.

Key differences from Praluent:

Administered by a healthcare provider in-office — no home injections or specialty pharmacy required

Given just twice per year after initial loading doses — dramatically fewer injections than Praluent

Covered under Medicare Part B (if given in-office) rather than Part D — may mean lower out-of-pocket for Medicare patients

Leqvio is an excellent option if you're struggling with self-injection adherence, pharmacy stocking issues, or Part D coverage gaps.

Alternative 3: Nexletol (Bempedoic Acid) — An Oral Option

For patients who prefer oral medication or can't access injectable biologics, bempedoic acid (Nexletol) is a once-daily tablet that lowers LDL-C by approximately 18–25% when added to statin therapy — significantly less potent than Praluent, but meaningful for many patients.

Bempedoic acid is also available in a fixed-dose combination with ezetimibe (Nexlizet), which together can reduce LDL-C by approximately 40%. It's available at most retail pharmacies and doesn't require specialty pharmacy access or prior authorization at the same level as PCSK9 inhibitors.

Important: Bempedoic acid carries a risk of elevated uric acid and gout, and is not a substitute for Praluent if you need aggressive LDL-C lowering. Discuss this with your doctor before switching.

39,483+ patients found their medications in stock

39K+

Find Praluent In Stock Today →

Alternative 4: Ezetimibe (Zetia) — Inexpensive, Oral, Widely Available

Ezetimibe (generic Zetia) reduces LDL-C by approximately 18–25% when added to a statin. It's inexpensive (generic available for as low as $15–$40/month), widely stocked at every retail pharmacy, and well-tolerated. If you haven't tried ezetimibe, many insurance plans require a documented trial before approving a PCSK9 inhibitor anyway — so starting ezetimibe while working out your Praluent access can serve double duty.

How to Choose: Talk to Your Doctor

No medication change should be made without consulting your prescribing provider. Your cardiologist or lipid specialist will consider your LDL-C target, cardiovascular risk level, insurance coverage, and tolerance for injections when recommending an alternative. Don't stop your current cholesterol-lowering regimen without guidance.

For more context on why Praluent is hard to access in the first place, see our guide on why Praluent is so hard to find.